Mesoblast Limited reported first-half FY2026 financial results demonstrating significant operational improvement, with total revenue reaching US$51.3 million, substantially driven by the commercial launch of Ryoncil® in the United States. Product revenue totaled US$48.7 million while gross profit reached US$44.2 million, reflecting strong pricing and market acceptance for the cell therapy treatment. The company's net loss narrowed considerably to US$40.2 million compared with US$47.9 million in the prior-year period, indicating improved financial efficiency as revenue growth outpaced expense increases.
The company has made substantial progress establishing its commercial infrastructure, onboarding 49 transplant centers toward its target of 64 facilities and securing insurance coverage for 280 million U.S. lives. These metrics indicate meaningful progress in building distribution channels and securing reimbursement pathways necessary for sustained market penetration. For the full FY2026 year, Mesoblast has guided Ryoncil® revenue in the range of US$110-120 million, suggesting continued momentum in adoption and utilization.
Beyond its commercial success with Ryoncil®, Mesoblast is advancing a pipeline of additional programs including Phase 3 clinical trials for chronic low back pain and heart failure indications. These development programs position the company to potentially expand its addressable market and revenue base in subsequent periods, contingent upon successful trial outcomes and regulatory approval.